Novo Nordisk's 2024 earnings exceeded estimates ... A highlight was the approval of Alhemo for treating hemophilia A and B in several major markets, including the United States and the European ...

Novo Nordisk's anti-TFPI antibody concizumab ... However, the two drugs are going after different indications. Alhemo is indicated for use in haemophilia A and B patients with inhibitors ...

Hympavzi's closest counterpart in the TFPI category is Novo ... as Alhemo, and last month was recommended for EU approval by the EMA's human medicines committee. The two drugs are directed at ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The drug has also been evaluated in adults and adolescents. Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025. Haemophilia A is a rare blood disorder ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...